Lilly and Nimbus Therapeutics have entered into a global research collaboration and exclusive licensing agreement to develop novel oral therapeutics for obesity and other metabolic diseases. The deal includes upfront and near-term payments of US$55 M, alongside potential development, regulatory and commercial milestones of up to US$1.3 B, as well as tiered royalties on future sales. Leveraging Nimbus’ AI-enabled computational drug discovery platform, the partnership aims to accelerate differentiated oral weight management treatments. With competition intensifying in the rapidly expanding obesity market, the collaboration strengthens Lilly’s metabolic pipeline while validating Nimbus’ discovery capabilities.